{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:13:32Z","timestamp":1782533612955,"version":"3.54.5"},"reference-count":24,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,9,15]]},"DOI":"10.2169\/internalmedicine.4653-20","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T22:09:38Z","timestamp":1591654178000},"page":"2281-2285","source":"Crossref","is-referenced-by-count":4,"title":["Severe Visceral Obesity, Fatty Liver and Diabetes after Orchiectomy for Prostate Cancer"],"prefix":"10.2169","volume":"59","author":[{"given":"Nobuo","family":"Kajitani","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Diabetes Center, Okayama City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetes Center, Okayama City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetes Center, Okayama City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hamahara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetes Center, Okayama City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Diabetes Center, Okayama City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Bo J-J, Zhang C, Zhang L-H, et al. Androgen deprivation therapy through bilateral orchiectomy: increased metabolic risks. Asian J Androl 13: 833-837, 2011."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24: 3979-3983, 2006.","DOI":"10.1200\/JCO.2006.05.9741"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Gild P, Cole AP, Krasnova A, et al. Liver disease in men undergoing androgen deprivation therapy for prostate cancer. J Urol 200: 573-581, 2018.","DOI":"10.1016\/j.juro.2018.03.135"},{"key":"4","unstructured":"4. Wang H, Sun X, Zhao L, Chen X, Zhao J. Androgen deprivation therapy is associated with diabetes: evidence from meta-analysis. J Diabetes Investig 7: 629-636, 2016."},{"key":"5","unstructured":"5. Sun M, Choueiri TK, Hamnvik O-PR, et al. Comparison of gonadotropin-releasing hormone agonists and orchiectomy: effects of androgen-deprivation therapy. JAMA Oncol 2: 500-507, 2016."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mitsuzuka K, Kyan A, Sato T, et al. Influence of 1 year of androgen deprivation therapy on lipid and glucose metabolism and fat accumulation in Japanese patients with prostate cancer. Prostate Cancer Prostatic Dis 19: 57-62, 2015.","DOI":"10.1038\/pcan.2015.50"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Levine Glenn N, D'Amico Anthony V, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. Circulation 121: 833-840, 2010.","DOI":"10.1161\/CIRCULATIONAHA.109.192695"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol 25: 45-53, 2018.","DOI":"10.1111\/iju.13473"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Cheung AS, Hoermann R, Dupuis P, Joon DL, Zajac JD, Grossmann M. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol 175: 229-237, 2016.","DOI":"10.1530\/EJE-16-0200"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 294: 238-244, 2005.","DOI":"10.1001\/jama.294.2.238"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Inaba M, Otani Y, Nishimura K, et al. Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism 54: 55-59, 2005.","DOI":"10.1016\/j.metabol.2004.07.010"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Matsushita Y, Nakagawa T, Yamamoto S, et al. Associations of visceral and subcutaneous fat areas with the prevalence of metabolic risk factor clustering in 6,292 Japanese individuals. Diabetes Care 33: 2117-2119, 2010.","DOI":"10.2337\/dc10-0120"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Navarro G, Allard C, Xu W, Mauvais-Jarvis F. The role of androgens in metabolism, obesity, and diabetes in males and females. Obesity 23: 713-719, 2015.","DOI":"10.1002\/oby.21033"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Harada N, Hanaoka R, Horiuchi H, et al. Castration influences intestinal microflora and induces abdominal obesity in high-fat diet-fed mice. Sci Rep 6: 23001, 2016.","DOI":"10.1038\/srep23001"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Whang A, Nagpal R, Yadav H. Bi-directional drug-microbiome interactions of anti-diabetics. EBioMedicine 39: 591-602, 2019.","DOI":"10.1016\/j.ebiom.2018.11.046"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Hamilton EJ, Gianatti E, Strauss BJ, et al. Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol 74: 377-383, 2011.","DOI":"10.1111\/j.1365-2265.2010.03942.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Nobes JP, Langley SEM, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int 109: 1495-1502, 2012.","DOI":"10.1111\/j.1464-410X.2011.10555.x"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kuchay MS, Krishan S, Mishra SK, et al. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care 41: 1801-1808, 2018.","DOI":"10.2337\/dc18-0165"},{"key":"19","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"19. Armstrong MJ, Gaunt P, Aithal GP, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387: 679-690, 2016.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Lee J, Hong S-W, Chae SW, et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice. PLOS ONE 7: e31394, 2012.","DOI":"10.1371\/journal.pone.0031394"},{"key":"21","unstructured":"21. Ishii S, Nagai Y, Sada Y, et al. Liraglutide reduces visceral and intrahepatic fat without significant loss of muscle mass in obese patients with type 2 diabetes: a prospective case series. J Clin Med Res 11: 219-224, 2019."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373: 2117-2128, 2015.","DOI":"10.1056\/NEJMoa1504720"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311-322, 2016.","DOI":"10.1056\/NEJMoa1603827"},{"key":"24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"24. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394: 121-130, 2019.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/18\/59_4653-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T03:44:35Z","timestamp":1600487075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/18\/59_4653-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":24,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4653-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}